Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...

Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...

Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target remains the same with $37.00. Terence Flynn has ...

Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.

Bristol-Myers Squibb won FDA approval for its novel schizophrenia drug, Cobenfy. BMY stock jumped, signaling a breakout.

Bristol-Myers Squibb (NYSE:BMY) shares rallied 4.45% in premarket trading Friday following the announcement that the U.S.

Bristol Myers Squibb (BMY) ended the recent trading session at $49.95, demonstrating a +0.46% swing from the preceding day's closing price. This move lagged the S&P 500's daily gain of 1.01%.

While not a mind-blowing move, it is good to see that the Bristol-Myers Squibb Company (NYSE:BMY) share price has gained 22% in the last three months. But that doesn't help the fact that the three ...

8 analysts have expressed a variety of opinions on Bristol-Myers Squibb BMY over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed ...